Rafael Rosell

Summary

Country: Spain

Publications

  1. pmc The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
    Laura Bonanno
    Second Medical Oncology Unit, Istituto Oncologico Veneto I R C C S, Via Gattamelata 64, Padova, Italia
    Oncotarget 4:1572-81. 2013
  2. doi request reprint Genetics and biomarkers in personalisation of lung cancer treatment
    Rafael Rosell
    Catalan Institute of Oncology Badalona, Spain
    Lancet 382:720-31. 2013
  3. doi request reprint A genetic snapshot of small cell lung cancer
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    Cancer Discov 2:769-71. 2012
  4. doi request reprint Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    Lancet Oncol 13:239-46. 2012
  5. pmc mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients
    Mariacarmela Santarpia
    Pangaea Biotech, USP Dexeus University Institute, Sabino Arana 5 19, Barcelona, 08028, Spain
    J Transl Med 9:163. 2011
  6. doi request reprint Biomarkers in lung oncology
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Pulm Pharmacol Ther 23:508-14. 2010
  7. doi request reprint Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Clin Cancer Res 17:1160-8. 2011
  8. doi request reprint Predicting response to chemotherapy with early-stage lung cancer
    Rafael Rosell
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Cancer J 17:49-56. 2011
  9. doi request reprint Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    Albert Font
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Crta Canyet s n, 08916, Badalona, Barcelona, Spain
    Cancer Chemother Pharmacol 62:1075-83. 2008
  10. doi request reprint Predictive biomarkers in the management of EGFR mutant lung cancer
    Rafael Rosell
    Catalan Institue of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Ann N Y Acad Sci 1210:45-52. 2010

Detail Information

Publications73

  1. pmc The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
    Laura Bonanno
    Second Medical Oncology Unit, Istituto Oncologico Veneto I R C C S, Via Gattamelata 64, Padova, Italia
    Oncotarget 4:1572-81. 2013
    ..9 months (P less than 0.0001) and overall survival was 8.2 months (P=0.001). The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy. ..
  2. doi request reprint Genetics and biomarkers in personalisation of lung cancer treatment
    Rafael Rosell
    Catalan Institute of Oncology Badalona, Spain
    Lancet 382:720-31. 2013
    ..Additionally, novel biomarkers could be identified through deep sequencing analysis of serial rebiopsies before and during treatment. ..
  3. doi request reprint A genetic snapshot of small cell lung cancer
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    Cancer Discov 2:769-71. 2012
    ..The knockdown of PARP1 and EZH2 abrogated SCLC growth. These findings provide the basis for novel predictive markers and new treatment strategies in SCLC, for which there is now a paucity of available therapies...
  4. doi request reprint Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    Lancet Oncol 13:239-46. 2012
    ..We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC...
  5. pmc mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients
    Mariacarmela Santarpia
    Pangaea Biotech, USP Dexeus University Institute, Sabino Arana 5 19, Barcelona, 08028, Spain
    J Transl Med 9:163. 2011
    ..In addition, NFKBIA and DUSP22 gene status was also determined...
  6. doi request reprint Biomarkers in lung oncology
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Pulm Pharmacol Ther 23:508-14. 2010
    ..It is plausible that several genetically defined subclasses of EGFR mutations could help to improve current clinical outcomes by combining erlotinib or gefitinib with other targeted drugs...
  7. doi request reprint Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Clin Cancer Res 17:1160-8. 2011
    ..However, the presence of EGFR mutations can only imperfectly predict outcome. We hypothesized that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways...
  8. doi request reprint Predicting response to chemotherapy with early-stage lung cancer
    Rafael Rosell
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Cancer J 17:49-56. 2011
    ..A 15-gene signature has identified JBR.10 patients who are more sensitive to adjuvant chemotherapy...
  9. doi request reprint Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
    Albert Font
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Crta Canyet s n, 08916, Badalona, Barcelona, Spain
    Cancer Chemother Pharmacol 62:1075-83. 2008
    ....
  10. doi request reprint Predictive biomarkers in the management of EGFR mutant lung cancer
    Rafael Rosell
    Catalan Institue of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Ann N Y Acad Sci 1210:45-52. 2010
    ..Mechanisms of resistance to reversible EGFR TKIs should be further clarified and could be related to modifications in DNA repair...
  11. ncbi request reprint Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery
    Enriqueta Felip
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Lung Cancer 6:299-303. 2005
    ..Hypoxia-inducible factor-1a expression levels analyzed by real-time quantitative PCR in surgery specimens after platinum/gemcitabine therapy do not correlate with the outcome of patients with stage II/III NSCLC...
  12. ncbi request reprint 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group
    Jose Luis Ramirez
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    J Clin Oncol 23:9105-12. 2005
    ..Methylation-dependent transcriptional silencing of 14-3-3sigma, a major G2-M checkpoint control gene, could be a predictor of longer survival...
  13. doi request reprint Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
    Enric Carcereny
    Catalan Institute of Oncology, Badalona, Spain
    Lung Cancer 68:491-7. 2010
    ..1-month progression-free survival, and 19-month median survival. CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0...
  14. ncbi request reprint Influence of genetic markers on survival in non-small cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona Barcelona, Spain
    Drugs Today (Barc) 39:775-86. 2003
    ..Genes involved in spindle formation, centrosome functions and mRNA transport along the microtubule tracks should provide further information on potential markers of docetaxel resistance...
  15. ncbi request reprint Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery
    Rafael Rosell
    Institut Catala d Oncologia, Medical Oncology Service, Hospital Germans Trias i Pujol, Barcelona, Spain
    Clin Cancer Res 10:4215s-4219s. 2004
    ....
  16. ncbi request reprint Applications of genomics in NSCLC
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, S N, 08916 Badalona, Barcelona, Spain
    Lung Cancer 50:S33-40. 2005
    ..ERCC1 is one of several proteins involved in the repairosome, where other DNA repair genes, such as BRCA1, are also central to cisplatin resistance...
  17. ncbi request reprint The promise of pharmacogenomics: gemcitabine and pemetrexed
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain
    Oncology (Williston Park) 18:70-6. 2004
    ..One can thus envision that substantial improvements in therapeutic outcome could benefit from the integration of tailored ribonucleotide reductase-dependent chemotherapy, ribonucleotide reductase antisense therapy, and targeted therapy...
  18. ncbi request reprint Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
    Rafael Rosell
    Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain
    Clin Cancer Res 10:1318-25. 2004
    ..Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity...
  19. ncbi request reprint Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
    Albert Font
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Invest New Drugs 21:435-43. 2003
    ....
  20. ncbi request reprint Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer
    Rafael Rosell
    Department of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Oncogene 22:3548-53. 2003
    ..The predictive value of beta-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival...
  21. doi request reprint A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells
    Miguel A Molina-Vila
    Catalan Institute of Oncology, Medical Oncology Service, Hosptial Germans Trias i Pujol, Badalona, Spain
    J Thorac Oncol 3:1224-35. 2008
    ..However, the number of tumor cells in a sample is often insufficient for EGFR assessment...
  22. ncbi request reprint Genetic testing for chemotherapy in non-small cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, S N, 08916 Barcelona, Badalona, Spain
    Lung Cancer 41:S97-102. 2003
    ..Patients are randomized to the control arm of cisplatin/docetaxel or to the experimental arm, where docetaxel is combined with cisplatin or gemcitabine according to ERCC1 levels. To date, 86 patients have been included...
  23. ncbi request reprint Targeted therapy in combination with gemcitabine in non-small cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Semin Oncol 30:19-25. 2003
    ..Preliminary findings that a subset of gemcitabine/cisplatin-treated patients with low ERCC1 and RRM1 mRNA levels show a significantly longer survival and highlight the possibilities of individually tailored chemotherapy...
  24. pmc Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    PLoS ONE 4:e5133. 2009
    ..In an exploratory analysis, we also examined the effect of RAP80 and Abraxas mRNA levels...
  25. doi request reprint Screening for epidermal growth factor receptor mutations in lung cancer
    Rafael Rosell
    Catalan Institute of Oncology and Autonomous University of Barcelona, Hospital Germans Trias i Pujol, Barcelona, Spain
    N Engl J Med 361:958-67. 2009
    ..We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment...
  26. doi request reprint First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
    Fernanda Salazar
    Catalan Institute of Oncology, Badalona, Spain
    Lung Cancer 72:84-91. 2011
    ..Second-line EGFR TKIs improved survival in patients receiving first-line cisplatin-based treatment. Unmethylated CHFR predicts increased survival to EGFR TKIs...
  27. ncbi request reprint Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Curr Opin Oncol 18:135-43. 2006
    ..This review highlights the numerous molecular biology findings in the field of lung cancer with potential therapeutic impact in both the near and distant future...
  28. ncbi request reprint Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Ctra Canyet, S N, 08916 Badalona Barcelona, Spain
    Lung Cancer 50:25-33. 2005
    ..The presence of EGFR mutations is a major determinant of gefitinib response, and EGFR tyrosine kinase inhibitors should be tested in clinical trials of first-line treatment of lung adenocarcinomas harboring EGFR mutations...
  29. ncbi request reprint Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer
    Vicente Alberola
    Medical Oncology Service, Hospital Arnau de Vilanova, Valencia, Spain
    Clin Lung Cancer 5:360-5. 2004
    ..Carriers of the MTHFR 677T allele could benefit from supplementation with folic acid and vitamin B12. The Spanish Lung Cancer Group has undertaken a phase III randomized trial to elucidate this concept...
  30. ncbi request reprint Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer
    Rafael Rosell
    Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Medical Oncology Service, Ctra Canyet, s n 08916 Badalona, Barcelona, Spain
    Expert Opin Pharmacother 11:1683-93. 2010
    ..Non-small-cell lung cancer (NSCLC) is a disseminated disease in 50% of cases, with a gloomy prognosis and median survivals of < 1 year...
  31. ncbi request reprint Predicting the outcome of chemotherapy for lung cancer
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, S N, 08916 Badalona, Spain, and Medical Oncology Unit, University of Messina, Italy
    Curr Opin Pharmacol 6:323-31. 2006
    ....
  32. ncbi request reprint Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Barcelona, Spain
    Cancer Control 10:297-305. 2003
    ....
  33. ncbi request reprint Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
    Miguel Taron
    Catalan Institute of Oncology, Pathology Department, Hospital Germans Trias i Pujol, Badalona, Spain
    Clin Cancer Res 11:5878-85. 2005
    ..Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) confer a strong sensitivity to gefitinib, a selective tyrosine kinase inhibitor of EGFR...
  34. pmc Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
    Sara Simonetti
    Pangaea Biotech, USP Dexeus University Institute, Barcelona, Spain
    J Transl Med 8:135. 2010
    ..Immunohistochemistry (IHC) with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients...
  35. ncbi request reprint How could pharmacogenomics help improve patient survival?
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s n 08916 Badalona Barcelona, Spain
    Lung Cancer 57:S35-41. 2007
    ..These findings are presented in this article, as well as their relevance in customising chemotherapy - illustrated by a hypothetical model guiding treatment decisions in the management of NSCLC...
  36. ncbi request reprint Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Clin Cancer Res 12:7222-31. 2006
    ..The five articles in this edition of CCR Focus will address the various mechanisms of EGFR pathway activation and provide insight into the potential for translation into clinical relevance...
  37. ncbi request reprint BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
    Miquel Taron
    Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Hum Mol Genet 13:2443-9. 2004
    ..020) compared with those in the top quartile. BRCA1 expression is potentially an important tool for use in cancer management and should be assessed for predicting differential chemosensitivity and tailoring chemotherapy in lung cancer...
  38. doi request reprint Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer
    Enriqueta Felip
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 28:3138-45. 2010
    ..To address whether preoperative chemotherapy plus surgery or surgery plus adjuvant chemotherapy prolongs disease-free survival compared with surgery alone among patients with resectable non-small-cell lung cancer...
  39. ncbi request reprint Pemetrexed in previously treated non-small-cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Institut Catala d Oncologia, Badalona Barcelona, Spain
    Oncology (Williston Park) 18:63-71. 2004
    ..Future clinical trials in NSCLC will include tailored and multitargeted therapy and pemetrexed represents a significant step forward in this direction...
  40. doi request reprint Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Clin Transl Oncol 12:75-80. 2010
    ..The sensitivity to EGFR TKIs could be greatly influenced by the expression of genes involved in the repair of DNA double-strand breaks by homologous recombination and non-homologous end joining...
  41. ncbi request reprint Molecular predictors of response to chemotherapy in lung cancer
    Rafael Rosell
    Medical Oncology Service, The Pathology Department, Hospital Germans Trias i Pujol, Insitut Català d Oncologia, Badalona Barcelona, Spain
    Semin Oncol 31:20-7. 2004
    ..MGMT methylation can be assessed in serum DNA. By assessing ERCC1 mRNA, cisplatin adducts, XPD polymorphism, Ape 1, and MGMT, we can obtain a complete genetic profile, which can be used in real translational research...
  42. pmc The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer
    Mireia Margeli
    Medical Oncology Service, Department of Medicine, Catalan Institute of Oncology, Hospital Germans Trias i Pujol and Autonomous University of Barcelona, Badalona, Spain
    PLoS ONE 5:e9499. 2010
    ..Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA...
  43. doi request reprint Translational research in glioblastoma multiforme: molecular criteria for patient selection
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, S N, 08916 Barcelona, Spain
    Future Oncol 4:219-28. 2008
    ..Translational clinical trials are warranted in order to detect the subgroups of patients resistant to radiotherapy who may derive benefit from novel therapies, including antiangiogenic drugs...
  44. doi request reprint Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Clin Lung Cancer 9:S76-82. 2008
    ..These findings highlight the importance of continual learning, and decision-making strategies for customizing treatment should reflect the limitations of our knowledge...
  45. doi request reprint Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients
    Carmen Balañá
    Medical Oncology Service, Catalan Institute of Oncology ICO, Hospital Germans Trias i Pujol, Carretera Canyet s n, Badalona, Barcelona, Spain
    Clin Transl Oncol 13:677-85. 2011
    ..Methylation of the promoter of the MGMT gene and MGMT protein expression are recognized as predictive markers for response to alkylating chemotherapy in glioblastoma (GB)...
  46. ncbi request reprint Determinants of response and resistance to cytotoxics
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain
    Semin Oncol 29:110-8. 2002
    ..With the gene corral that will emerge from this trial, we will create an up-front diagnostic test for selecting the most appropriate gemcitabine plus cisplatin regimen for the treatment of non-small cell lung cancer...
  47. doi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
    Rafael Rosell
    Catalan Institue of Oncology, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
    Curr Opin Oncol 22:112-20. 2010
    ..We review here the clinical benefits of targeted therapy with erlotinib and gefitinib in white and Asian nonsmall-cell lung cancer patients...
  48. ncbi request reprint Platinum resistance related to a functional NER pathway
    Rafael Rosell
    Medical Oncology Service, Catalan Institute of Oncology, Badalona, Spain
    J Thorac Oncol 2:1063-6. 2007
  49. ncbi request reprint BRCA1: a new genomic marker for non-small-cell lung cancer
    Noemi Reguart
    Medical Oncology Service, Catalan Institute of Oncology, ICO, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Clin Lung Cancer 9:331-9. 2008
    ..This report provides a review on the breast cancer susceptibility gene 1, a promising gene determinant of response to different types of chemotherapy and its potential applications as a new molecular marker in lung cancer...
  50. ncbi request reprint Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients
    Jose Luis Ramirez
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, s n 08916, Barcelona, Spain
    Cancer Lett 193:207-16. 2003
    ..K-ras mutations in serum correlated significantly with survival (P=0.01)...
  51. ncbi request reprint Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy
    Rosario Garcia-Campelo
    Medical Oncology Service, Hospital Juan Canalejo, As Xubias, 84, 15006, A Coruna, Spain
    Expert Opin Pharmacother 6:2015-26. 2005
    ..In this article, the authors try to highlight the more relevant aspects regarding these issues, primarily focused on the potential role of ERCC1, RRM1, XPD and BRCA1 expression profiling as predictors of anticancer drug efficacy...
  52. ncbi request reprint O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme
    Carme Balañà
    Medical Oncology Service, Hospital Germans Trias i Pujol, 08916 Badalona Barcelona, Spain
    Clin Cancer Res 9:1461-8. 2003
    ..Although GBM grows within the skull, we investigated the concordance of methylation in glioma tissue, and paired serum DNA and the potential correlation with response and time to progression...
  53. ncbi request reprint DNA repair and cisplatin resistance in non-small-cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, S N, 08916 Barcelona, Badalona, Spain
    Lung Cancer 38:217-27. 2002
    ..Some DNA repair genes, like ERCC1, have been shown to be crucial in predicting cisplatin resistance and can be used for tailoring cisplatin-based chemotherapy...
  54. ncbi request reprint Future directions in the second-line treatment of non-small cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Semin Oncol 33:S45-51. 2006
    ..At the preclinical level, small interfering RNA sequences have been used successfully to neutralize multiple abnormal components of the Wnt pathway...
  55. ncbi request reprint Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
    Jose Miguel Sanchez
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet s n, 08916 Badalona, Barcelona, Spain
    Lung Cancer 38:309-15. 2002
    ..Non-hematologic toxicities were mild in all three schedules. For future studies, schedule A with lower doses is recommended...
  56. ncbi request reprint Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response
    Enriqueta Felip
    Head Lung Cancer Unit, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Expert Rev Mol Diagn 7:261-8. 2007
    ..At present, molecular markers, such as ERCC1, represent a potential parameter to help guide clinical treatment decisions. Prospective pharmacogenomic studies are therefore a research priority in NSCLC...
  57. pmc BRCA1: a novel prognostic factor in resected non-small-cell lung cancer
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    PLoS ONE 2:e1129. 2007
    ....
  58. ncbi request reprint Platinum drugs and DNA repair mechanisms in lung cancer
    Laura Bonanno
    Second Medical Oncology Unit, Istituto Oncologico Veneto IRCCS, Via Gattamelata 64, 35128 Padova, Italy
    Anticancer Res 34:493-501. 2014
    ....
  59. ncbi request reprint BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations
    Niki Karachaliou
    Pangaea Biotech, Dexeus University Institute, Barcelona, Spain
    J Thorac Oncol 8:295-300. 2013
    ..However, patients ultimately relapse, indicating that other genetic factors could influence outcome in such patients. We hypothesized that PFS could be influenced by the expression of genes in DNA repair pathways...
  60. ncbi request reprint Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations
    Rafael Rosell
    Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, Badalona, Barcelona, Spain
    Future Oncol 1:319-22. 2005
  61. ncbi request reprint Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy
    Carlos Camps
    Servicio de Oncologia Medica, Hospital General Universitario, Valencia, Spain, Laboratorio de Oncologia Molecular, Fundación Investigación, Hospital General Universitario, Valencia, Spain
    Clin Lung Cancer 8:369-75. 2007
    ..Herein, we discuss current knowledge regarding gene expression and polymorphisms of DNA repair enzymes in regard to cancer susceptibility and response to chemotherapy...
  62. ncbi request reprint Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer
    Rafael Rosell
    Hospital Germans Trias i Pujol, Medical Oncology Service, Ctra Canyet, s n 08916 Badalona, Barcelona, Spain
    Lung Cancer 38:43-9. 2002
    ..It also appears from xenograft data that C225 enhances the sensitivity of tumors to radiation and docetaxel or the combination...
  63. ncbi request reprint Clinical experience with erlotinib in non-small-cell lung cancer
    Enriqueta Felip
    Vall d Hebron University Hospital, Barcelona, Spain
    Drugs Today (Barc) 42:147-56. 2006
    ..Intense research activity is ongoing to validate known predictive markers and to discover new tools which maximize clinical benefit using erlotinib. However, there is no conclusive evidence, as yet, linking response to survival...
  64. ncbi request reprint Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors
    Rafael Rosell
    Medical Oncology Service, Scientific Director of Oncology Research Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s n 08916 Badalona Barcelona Spain
    Future Oncol 3:277-83. 2007
    ..To clarify this important issue, the Spanish Lung Cancer Group has opened a Phase III trial comparing erlotinib with chemotherapy in stage IV NSCLC patients with EGFR mutations. This study is open to other European institutions...
  65. ncbi request reprint Screening for EGFR mutations in lung cancer
    Miguel A Molina-Vila
    Medical Oncology Service, Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Catalunya, Spain
    Discov Med 8:181-4. 2009
    ..Large-scale screening for EGFR mutations in such patients is feasible for predicting response to TKIs and thus guiding treatment...
  66. ncbi request reprint World conference on lung cancer
    Enriqueta Felip
    Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Expert Opin Biol Ther 3:1295-8. 2003
    ..The Vancouver programme included > 140 invited speakers throughout the 'meet the professor', plenary and interactive sessions, as well as 300 oral and 500 poster presentations...
  67. ncbi request reprint Emerging drugs for non-small-cell lung cancer
    Enriqueta Felip
    Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Ctra Canyet s n, 08916 Badalona, Barcelona, Spain
    Expert Opin Emerg Drugs 12:449-60. 2007
    ..The review focuses on a number of new targeted agents/chemotherapy drugs now in clinical trials directed at improving NSCLC management. Mature results regarding their activity and usefulness can be expected in the near future...
  68. doi request reprint A prognostic DNA methylation signature for stage I non-small-cell lung cancer
    Juan Sandoval
    Juan Sandoval, Jesus Mendez Gonzalez, F Javier Carmona, Sergi Sayols, Sebastian Moran, Holger Heyn, Miguel Vizoso, Antonio Gomez, Montse Sanchez Cespedes, and Manel Esteller, Bellvitge Biomedical Research Institute Josefina Mora, Hospital de la Santa Creu i Sant Pau Manel Esteller, University of Barcelona and Institucio Catalana de Recerca i Estudis Avançats, Barcelona Miquel Taron and Rafael Rosell, Catalan Institute of Oncology, Badalona, Catalonia Marina Pollan, Instituto de Salud Carlos III, Madrid Maria J Pajares and Luis M Montuenga, University of Navarra Wenceslao Torre, Clínica University de Navarra, Pamplona, Spain Ernest Nadal, Guoan Chen, and David G Beer, University of Michigan Medical School, Ann Arbor, MI Yassen Assenov and Fabian Müller, Max Planck Institute, Saarbrucken, Germany Christoph Bock, Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria Lucia A Muscarella, Center for Rehabilitation Research
    J Clin Oncol 31:4140-7. 2013
    ..We aimed to find DNA methylation markers that could be helpful in this regard...
  69. ncbi request reprint Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer
    Carme Sarries
    Medical Oncology Service, Hospital Germans Trias i Pujol, Barcelona, Spain
    Pharmacogenomics 3:763-80. 2002
    ..Hopefully, the assessment of Src and of STAT-3 can be implemented as predictive markers...
  70. ncbi request reprint Pemetrexed combination therapy in the treatment of non-small cell lung cancer
    Rafael Rosell
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Semin Oncol 29:23-9. 2002
    ..Mechanisms of resistance to pemetrexed need to be investigated, including the potential role of TS messenger RNA. In summary, pemetrexed has emerged as a promising new cytotoxic drug in the arsenal of chemotherapy treatments for NSCLC...
  71. ncbi request reprint Cancer treatments: can we find treasures at the bottom of the sea?
    Mariano Provencio
    Medical Oncology Service, Hospital Universitario Clinica Puerta de Hierro, Madrid, Spain
    Clin Lung Cancer 10:295-300. 2009
    ..PM02734 is a closely related derivative of KF with similar activity and characteristics. Herein, we summarize the studies of PM02734 and future clinical perspectives...
  72. doi request reprint A modified host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes
    Pedro Mendez
    Health Science Research Institute Germans Trias i Pujol, Badalona, Barcelona, Spain
    DNA Repair (Amst) 10:603-10. 2011
    ..The results indicate that our method is highly sensitive, reliable and reproducible, and thus, it suitable for population-based studies to quantify in vitro DNA-repair deficiencies...
  73. ncbi request reprint The role of Wnt signaling in cancer and stem cells
    Noemi Reguart
    Catalan Institute of Oncology, Scientific Director of Oncology Research, Hospital Germans Trias i Pujol, Ctra Canyet, Barcelona, Spain
    Future Oncol 1:787-97. 2005
    ..In addition, Wnt signaling pathways also play a crucial role in normal tissue regeneration and stem cell self-renewal, raising the possibility of controlling immature tumor stem cells...